Haemophilus influenzae Type b Vaccine Immunogenicity in American Indian/Alaska Native Infants.

Autor: Jackson BD; Center for Indigenous Health., Miernyk K; Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska., Steinberg J; Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska., Beaudry J; Center for Indigenous Health., Christensen L; Indian Health Service, US Department of Health and Human Services, North Bethesda, Maryland., Chukwuma U; Indian Health Service, US Department of Health and Human Services, North Bethesda, Maryland., Clichee D; Center for Indigenous Health., Damon S; Indian Health Service, US Department of Health and Human Services, North Bethesda, Maryland., Farrenkopf BA; Center for Indigenous Health., Hurley C; Center for Indigenous Health., Luna J; Tséhootsooí Medical Center, Fort Defiance, Arizona., Simons B; Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska., Singleton R; Alaska Native Tribal Health Consortium, Anchorage, Alaska., Thomas M; Center for Indigenous Health., VanDeRiet D; Center for Indigenous Health., Weatherholtz R; Center for Indigenous Health., Zeger S; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore., Zylstra S; Center for Indigenous Health., Keck J; Alaska Native Tribal Health Consortium, Anchorage, Alaska., Hammitt LL; Center for Indigenous Health.

Publikováno v: Pediatrics [Pediatrics] 2024 Oct 01; Vol. 154 (4).

Limitations in the clinical utility of vaccine challenge responses in the evaluation of primary antibody deficiency including Common Variable Immunodeficiency Disorders.

Autor: Ameratunga R; Department of Clinical Immunology, Auckland Hospital, Park Rd, Grafton, 1010, Auckland, New Zealand; Department of Virology and Immunology, Auckland Hospital, Park Rd, Grafton, 1010 Auckland, New Zealand; Department of Molecular Medicine and Pathology, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Park Rd, Grafton Auckland 1010, New Zealand. Electronic address: rohana@adhb.govt.nz., Longhurst H; Department of Virology and Immunology, Auckland Hospital, Park Rd, Grafton, 1010 Auckland, New Zealand; Department of Medicine, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Park Rd, Grafton Auckland 1010, New Zealand., Leung E; Maurice Wilkins Centre, School of Biological Sciences, University of Auckland, Symonds St, Auckland, New Zealand; Auckland Cancer Society Research Centre, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand., Steele R; Department of Virology and Immunology, Auckland Hospital, Park Rd, Grafton, 1010 Auckland, New Zealand; Department of Respiratory Medicine, Wellington Hospital, Wellington, New Zealand., Lehnert K; Department of Respiratory Medicine, Wellington Hospital, Wellington, New Zealand; Applied Translational Genetics, School of Biological Sciences, University of Auckland, Auckland, New Zealand; Centre for Brain Research, Faculty of Health and Medical Sciences, University of Auckland, Symonds St, Auckland 1010, New Zealand., Woon ST; Department of Virology and Immunology, Auckland Hospital, Park Rd, Grafton, 1010 Auckland, New Zealand; Department of Molecular Medicine and Pathology, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Park Rd, Grafton Auckland 1010, New Zealand.

Publikováno v: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2024 Sep; Vol. 266, pp. 110320. Date of Electronic Publication: 2024 Jul 25.

A prospective, observational, multi-center, post-marketing safety surveillance study of the GSK combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b invasive infections (DTaP-IPV/Hib) in South Korean infants.

Autor: Elenge DM; GSK, Wavre, Belgium., Heo JS; Department of Pediatrics, Korea University College of Medicine, Seoul, South Korea., Kim SS; Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, South Korea., Kim YK; Department of Pediatrics, Korea University College of Medicine, Seoul, South Korea., Lee JH; Department of Pediatrics, Ajou University School of Medicine, Suwon, South Korea., Xavier S; GSK, Bangalore, India., Bahar E; GSK, Wavre, Belgium., Dos Santos G; GSK, Wavre, Belgium., Guignard A; GSK, Wavre, Belgium.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2406060. Date of Electronic Publication: 2024 Oct 08.

Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study.

Autor: Zhu Y; Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China., Sun L; Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China., Wang Y; Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China., Wang J; Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China., Wang Y; Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China., Li J; Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China., Wang L; Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China., Guo Y; Management of Immunization programmes, Hebei Province Center for Disease Prevention and Control, Shijiazhuang, P.R. China.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2372884. Date of Electronic Publication: 2024 Jul 03.

Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule.

Autor: Martinón-Torres F; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.; Genetics, Vaccines and Infectious Diseases Research Group (GENvip), Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.; Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain., Salamanca de la Cueva I; Instituto Hispalense de Pediatría, Sevilla, Spain., Horn M; Praxis Dr. med. Michael Horn, Bayern, Schoenau am Koenigssee, Germany., Westerholt S; Praxis für Kinder und Jugendmedizin Drs. Westerholt/Matyas, Wolfsburg, Germany., Bosis S; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy., Meyer N; GSK, Wavre, Belgium., Cheuvart B; GSK, Wavre, Belgium., Virk N; GSK, Mumbai, India., Jakes RW; GSK, London, UK., Duchenne M; GSK, Wavre, Belgium., Van den Steen P; GSK, Wavre, Belgium.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2342630. Date of Electronic Publication: 2024 Apr 30.